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Outcome measure Evidence Implications
Patient-oriented evidence
Prolongation of OS Substantial Median OS is significantly longer with bortezomib than with standard high-dose
dexamethasone therapy, maintained during extended follow-up
Improvement of 1-year survival rate Substantial Significantly more patients survive for 1 year with bortezomib than with standard 
high-dose dexamethasone therapy
Prolongation of TTP Substantial Median TTP is significantly longer with bortezomib than with standard high-dose
dexamethasone therapy
Adverse events  Moderate A significantly higher proportion of patients treated with bortezomib than with 
standard high-dose dexamethasone therapy report grade 3 adverse events, mainly
thrombocytopenia or neutropenia. However, the rates of grade 4 adverse events 
and serious adverse events appear to be similar with bortezomib and high-dose
dexamethasone
Reduction of skeletal events No evidence Further studies required 
Infections  Limited The rate of grade ≥3 infection did not differ significantly between bortezomib and 
high-dose dexamethasone. However, a significantly higher proportion of patients 
treated with bortezomib than with standard high-dose dexamethasone therapy
experience herpes zoster infections
Improvement of quality of life Moderate Patient-reported outcomes improve with bortezomib
Disease-oriented evidence
Improvement of response rate 
(complete plus partial response)
Substantial A significantly higher proportion of patients treated with bortezomib than with
standard high-dose dexamethasone therapy respond to treatment
Duration of response Substantial Bortezomib therapy produces durable responses
Economic evidence
Cost effectiveness Limited Further studies required
OS, overall survival; TTP, time to progression.
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Abstract
Introduction: Multiple myeloma is a relatively common and incurable form of hematologic malignancy for which there is currently no
single standard therapy. Bortezomib inhibits the 20S proteasome involved in the degradation of intracellular proteins, induces apoptosis,
reverses drug resistance in multiple myeloma cells, and influences their microenvironment by blocking cytokine circuits, cell adhesion
and angiogenesis in vivo.
Aims: The objective of this review is to evaluate the evidence for the use of bortezomib in the treatment of multiple myeloma. 
Evidence review: In patients with relapsed multiple myeloma bortezomib significantly prolongs overall survival and time to progression,
and improves response rates, duration of response, and quality of life compared with oral high-dose dexamethasone. Although the
incidence of grade 4 adverse events was similar, grade 3 events and herpes zoster infections occur more frequently in patients treated
with bortezomib than with high-dose dexamethasone. Evidence from a pharmacoeconomic study indicates that the benefits of
bortezomib compared to thalidomide plus best standard care may be achieved at a reasonable cost. 
Clinical value: Bortezomib is a valuable treatment option in the management of relapsed multiple myeloma that improves survival and
delays disease progression compared with oral high-dose dexamethasone treatment, albeit with an increased incidence of some
adverse events such as grade 3 thrombocytopenia and neutropenia. 
Key words: bortezomib, evidence, multiple myeloma, outcomes, treatmentScope, aims, and objectives
Multiple myeloma is an incurable form of hematologic cancer.
Bortezomib (LDP-341, MG-341, MLN-341, PS-341, Velcade®)
inhibits the 20S proteasome involved in the degradation of
intracellular proteins, including those affecting cell cycle
regulation in mammalian cells. The objective of this review is to
evaluate the evidence for the use of bortezomib in the treatment
of relapsed or refractory multiple myeloma. 
Methods
The English language medical literature was reviewed for
appropriate articles relating to bortezomib for the treatment of
multiple myeloma. The following databases were searched on
September 2, 2005 using the search terms “Bortezomib OR 
LDP-341 OR MG-341 OR MLN-341 OR PS-341 OR Velcade AND
multiple myeloma”. The cut-off date was from the beginning of
the database to the date of the search unless otherwise stated. 
• PubMed, http://www.ncbi.nlm.nih.gov/entrez, 1966 to date
• EMBASE, http://www.datastarweb.com, 1974 to date
• Centre for Reviews and Dissemination (CRD) databases
[Database of Abstracts of Reviews of Effects (DARE); Health
Technology Assessment (HTA); National Health Service (NHS)
Economic Evaluations Database (NHSEED)],
http://www.york.ac.uk/inst/crd/crddatabases.htm
• Cochrane Database of Systematic Reviews (CDSR),
http://www.cochrane.org
• Clinical Evidence (BMJ), http://www.clinicalevidence.com
• BIOSIS, http://www.datastarweb.com
• National Guideline Clearinghouse, http://www.guideline.gov
• National Institute for Health and Clinical Excellence,
http://www.nice.org.uk
• Clinical trial registers, http://www.clinicaltrials.gov,
http://www.clinicalstudyresults.org
• American Society of Clinical Oncology,
http://www.asco.org/asco/publications
Following hand-searching, no systematic reviews were identified
for the use of bortezomib in multiple myeloma, two papers and
two abstracts were of level 2 evidence, and there were four
papers and one abstract of level ≥3 evidence (including economic
evidence) (Table 1). 
A further search of the English language literature on PubMed using
the search terms “bortezomib in multiple myeloma,” “clinical trial,”
“meta analysis,” “randomized controlled trial,” and “humans” was
conducted with the date limits September 1, 2005 to May 24, 2006.
The limits were imposed to provide specificity to the search.
Eleven records were found, of which two were excluded because
they were nonsystematic reviews (n=1) or a case study (n=1). 
A further PubMed search between May 25 and June 26, 2006
identified two additional relevant studies. Finally, a search of 
the 2005 Annual Meeting of the American Society of Hematology
(http://www.hematology.org) revealed 28 further abstracts. 
Hand-searching resulted in 12 being included; the remaining
subanalyses (n=1), interim analysis of phase I/II trials (n=4), use in
previously untreated patients (n=6), observational usage studies
(n=1), case series (n=1), off-label regimen (n=1), and duplicates
(n=2) were excluded. 
Disease overview
Multiple myeloma is a malignant proliferation of plasma cells which
is characterized by the presence of paraproteins in the serum, 
bone marrow infiltration, bone destruction, and renal impairment 
(ACS 2005a; NCI 2005). With conventional treatments, multiple
myeloma remains an incurable disease, and patients have a 
median survival of 3–4 years with a 5-year relative survival rate of
approximately 32% (UK Myeloma Forum Guidelines Working
Group 2001; Barlogie et al. 2004; ACS 2005a). 
Epidemiology
Multiple myeloma accounts for about 10% of all hematologic
malignancies (ACS 2005b). In the USA and the UK, respectively,
about 15 000 and 2500–3000 new cases of multiple myeloma are
reported annually (Joshua & Gibson 2002; Kyle et al. 2003; 
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Category Number of records
Full papers Abstracts
Initial search 209 31
records excluded 202 25
records included 7 6
Additional studies identified 2 0
Search update, new records 11 28
records excluded 2 16
records included 9 12
Level 1 clinical evidence 1 1
Level 2 clinical evidence 5 4a
Level ≥3 clinical evidence 11a 12a
trials other than RCT 11 12
case reports 0 0
Economic evidence 1 1
For definition of levels of evidence, see Editorial Information on inside back cover.
aFive of these records are extensions of original trials and/or pooled analyses.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the reviewMorgan & Davies 2005). Potential risk factors for multiple myeloma
that have been studied include: declining immune function, genetic
factors, certain occupations, exposure to radiation, and exposure to
certain chemicals (MMRF 2005a; NCI 2005). However, no strong
associations between potential risk factors and multiple myeloma
have been noted and, in most cases, individuals who develop
multiple myeloma have no clear risk factors (MMRF 2005a; NCI
2005). Multiple myeloma is predominantly a disease of the elderly,
with most cases diagnosed in patients over 65 years of age and the
level of risk seems to be highest among groups of African ethnic 
origin (NCI 2005). A history of monoclonal gammopathy of
undetermined significance, in which abnormal plasma cells make a
low level of monoclonal immunoglobulin [myeloma (M)] proteins, has
also been associated with increased risk of multiple myeloma (NCI
2005). However, most people with these known risk factors do not
get multiple myeloma (NCI 2005). Unfortunately, the economic
burden imposed by multiple myeloma has not been well quantified
(Mehta et al. 2004). 
Clinical features
The clinical course of patients with multiple myeloma varies
markedly (Harousseau et al. 2004). Bone marrow infiltration due to
overgrowth of plasma cells leads to anemia, thrombocytopenia, and
leukopenia. Active bone resorption, due to increased osteoclast
activity, also leads to bone pain, vertebral collapse, fractures,
hypercalcemia, and renal impairment (ACS 2005a; NCI 2005). 
In addition, reductions in the normal levels of immunoglobulins
contribute to the tendency for patients with multiple myeloma to
have recurrent infections (MMRF 2005a; NCI 2005).
Diagnosis
The diagnosis of multiple myeloma is often made incidentally
during routine blood tests for other conditions such as anemia.
Laboratory tests performed on blood and/or urine to help confirm
a diagnosis of myeloma include: complete blood count; chemistry
profile; serum beta 2-microglobulin (beta 2-M); C-reactive protein;
quantitative immunoglobulins; serum and urine protein
electrophoresis; and 24-hour urine protein. The quantification of
serum-free immunoglobulin light chain levels (FLC assay) and
kappa/lamda ratio can be used as an alternative to quantifying
urinary light chains. The serum tests are particularly useful 
for diagnosis and monitoring free light chain only myeloma and
patients in whom the serum and urine is negative on
immunofixation (nonsecretory myeloma). In addition, X-ray
imaging, magnetic resonance imaging (MRI), and computerized
tomography (CT) scans may be used to assess changes in bone
structure as well as number and size of bone lesions; bone
marrow aspiration/biopsy is used to assess the number of plasma
cells in bone marrow (ACS 2005a; MMRF 2005b; NCI 2005; UK
Nordic Guidelines Working Group 2005). 
Disease staging
The Durie–Salmon staging system (Durie & Salmon 1975) is the
most commonly utilized staging system for patients with multiple
myeloma (Table 2) (MMRF 2005b). 
In this system, the clinical stage of disease (stage I, II, or III) is
based on four measurements: levels of M protein, number of bone
lesions, hemoglobin values, and serum calcium levels. The stages
are also classified further (as A or B) according to renal function.
However, increasingly, physicians are relying less on the
Durie–Salmon staging system and more on biologically relevant
markers as prognostic indicators when making treatment choices.
A new International Staging System (ISS) for myeloma has
recently been proposed, based on measurement of serum levels
of beta 2-M and albumin (Table 2), that separates patients into
three prognostic groups irrespective of type of therapy 
(Greipp et al. 2003), and which appears to provide better
discrimination between staging groups. Incorporation of
cytogenetic data into the ISS may further improve staging (UK
Nordic Guidelines Working Group 2005). 
Evaluation of response
In 1998, the European Group for Blood and Marrow Transplant
(EBMT) proposed strict criteria for the assessment of complete
response (CR) in patients with multiple myeloma undergoing
stem cell transplantation (SCT) (Bladé et al. 1998). These criteria
include the complete absence of M protein by immunofixation
techniques as well as by serum and urine protein
electrophoresis (SPEP and UPEP). In addition, partial response
(PR) was defined as a reduction of M protein in serum of at 
Stage Durie–Salmon criteria ISS criteria
I All of the following:
• Hemoglobin >10 g/dL
• Serum calcium normal or ≤12 mg/dL
• Bone X-ray, normal bone structure
(scale 0) or solitary bone
plasmacytoma only
• Low M-component production rate
— IgG <5 g/dL; IgA <3 g/dL
• Bence Jones protein <4 g/24 h
Beta 2-M <3.5 and albumin
≥3.5 mg/L (median survival 
62 months)
II Neither stage I nor stage III Neither stage I nor stage IIIa
(median survival 45 months)
III One or more of the following:
• Hemoglobin <8.5 g/dL
• Serum calcium >12 mg/dL
• Advanced lytic bone lesions (scale 3)
• High M-component production rate
— IgG >7 g/dL; IgA >5 g/dL
— Bence Jones protein >12 g/24 h
Beta 2-M >5.5 mg/L
(median survival 29 months)
Durie–Salmon subclassifications (either A or B):
A: Relatively normal renal function (serum creatinine <2.0 mg/dL)
B: Abnormal renal function (serum creatinine ≥2.0 mg/dL)
aIn the ISS stage II there are two subcategories: 
Serum beta 2-M <3.5 mg/L, but serum albumin <3.5 g/dL, or 
Serum beta 2-M 3.5–5.5 mg/L irrespective of the serum albumin level 
Beta 2-M, beta 2-microglobulin; h, hour; Ig, immunoglobulin; ISS, International Staging
System; M, myeloma.
Table 2 | The Durie-Salmon and ISS Myeloma staging systems
(Greipp et al. 2003; MMRF 2005b)
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response (MR) was defined as a reduction of M protein in serum
of 25–49% and a reduction in urine of 50–89%. Progressive
disease (PD) was defined by any of the following: an increase of
M protein in serum or urine of >25%, an increase in bone
marrow plasma cells of >25%, new or increased bone lesions or
plasmacytomas, or new hypercalcemia. Furthermore, CR, PR,
and MR have to be confirmed by repeated measurements of 
M protein in serum and urine after 6 weeks, and PD has to be
confirmed by repeated measurements of M protein in serum and
urine after 1–3 weeks. Near-complete response (nCR), a
subcategory of PR, was defined as a CR with a positive
immunofixation test (lower limit of detection, 0.15–0.25 mg/mL).
Unfortunately, not all studies in patients with multiple myeloma
have used the EBMT criteria and therefore, because they have
used less-stringent criteria, it is not possible to directly compare
response rates between treatments. 
In clinical trials in patients with multiple myeloma it has been
regarded as important to distinguish between agents that
produce good but transient responses and those for which overall
responses may be less but which may be maintained for longer
(Morgan & Davies 2005). In view of the incurable nature of multiple
myeloma, overall survival (OS) has traditionally been considered
to be the major endpoint for a single line of treatment. However,
patients with myeloma typically receive multiple courses of
treatment during the course of the disease, the sequencing of
which may or may not be important. In view of this there is a need
to distinguish between survival and progression, and also to
recognize that OS may be affected by subsequent treatment
regimens (Morgan & Davies 2005). 
Goals of therapy
Treatment regimens for multiple myeloma are designed to meet a
variety of different therapeutic goals, which can include:
eradication of all evidence of disease; control of disease activity
to prevent damage to other organs; preservation of normal
performance and quality of life for as long as possible with
minimal intervention; provision of lasting relief of pain and other
disease symptoms; and long-term management of myeloma that
is in remission, when applicable (MMRF 2005a).
Current therapy options for multiple myeloma
There is currently no single standard therapy for active multiple
myeloma although, since the introduction of high-dose
melphalan treatment (McElwain & Powles 1983), the superiority
of high-dose therapy (HDT) with SCT over conventional
chemotherapy in selected patients with newly diagnosed disease
has been established in two large-scale, randomized controlled
trials (Attal et al. 1996; Child et al. 2003). However, HDT is 
not suitable for all patients. Recently, greater understanding 
of the pathogenesis of multiple myeloma has led to the
introduction of novel therapies such as thalidomide, lenalidomide,
and bortezomib (Singhal et al. 1999; Richardson et al. 2002;
Cavenagh & Oakervee 2003; Richardson et al. 2003; Richardson 
et al. 2005a). 
Conventional chemotherapy
The benefit of single-agent cyclophosphamide was shown to be
equivalent to the alkylating agent melphalan in an early Medical
Research Council (MRC) trial (MRC 1980) and, in the 1980s, a
number of trials investigated the use of combination
chemotherapy compared to single-agent melphalan. In particular,
the ABCM regimen (doxorubicin, carmustine, cyclophosphamide,
and melphalan) was compared to melphalan alone in the MRC
Myeloma V trial which showed significant benefits in favor of the
combination in terms of achievement of plateau disease and in
OS (MacLennan et al. 1992). In contrast, in a collaborative
worldwide overview of randomized trials of combination
chemotherapy versus melphalan plus prednisone (MP), no
evidence of any significant difference in mortality between
combination chemotherapy and MP was noted (MTCG 1998).
However, unlike the ABCM regimen, relatively few of the
combination regimens included the use of an anthracycline such
as doxorubicin.
High-dose chemotherapy, corticosteroids, and stem cell
transplants
The escalation of melphalan dosage to 140 mg/m2 was found to
improve response rates, with CR reported in approximately 30%
of patients, and it also produced evidence of bone healing
(McElwain & Powles 1983). Subsequently, the development of
autologous SCT has allowed escalation of melphalan dosage to
200 mg/m2 and has led to further improvements in CR rates
compared with standard doses of oral melphalan (Barlogie et al.
1999; Davies et al. 2001). High response rates (84%) have also
been reported with high-dose dexamethasone, in combination
with vincristine and doxorubicin (VAD), as first-line therapy for
multiple myeloma (Samson et al. 1989). The major advantage of
this regimen is its lack of adverse effects on the hematopoietic
stem cell compartment (Samson et al. 1989), which makes 
it useful for harvesting stem cells prior to autologous
transplantation. However, it has been estimated that
approximately 85% of the therapeutic effect of VAD can be
attributed to the dexamethasone component (Alexanian et al.
1992; Sonneveld et al. 2001). The HDT strategy that has been
developed consists of initial treatment with VAD to induce disease
response, at which point hematopoietic stem cells are harvested.
These cells are then used to support high-dose melphalan
treatment in order to consolidate the responses obtained.
Analyses of the effect of response after high-dose treatment have
suggested that patients achieving a CR had better 
progression-free survival (PFS) and OS than those who did not
(Barlogie et al. 1999; Lahuerta et al. 2000; Davies et al. 2001). It has
also been shown that two successive SCTs significantly improves
OS compared with single SCT following HDT (Attal et al. 2003).
Thalidomide
Early studies on the use of thalidomide as a single agent in
patients with relapsed refractory multiple myeloma produced a
promising 30% response rate (Singhal et al. 1999). As thalidomide
is not a cytotoxic agent these results provided a rationale for
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adding it to standard treatment regimens for patients deemed
unsuitable for SCT. For example, preliminary studies have
suggested that a CR rate of 22%, comparable to that achieved
with HDT, can be achieved by adding thalidomide to MP
chemotherapy (Palumbo et al. 2003). This regimen also produces
higher response rates and 3-year survival rates than MP alone
(Palumbo et al. 2006). Low-dose thalidomide plus
dexamethasone is better than conventional chemotherapy as a
first salvage regimen in patients with relapsed or refractory
multiple myeloma (Palumbo et al. 2004). The dexamethasone,
thalidomide, cisplatin, doxorubicin, cyclophosphamide, and
etoposide (DT-PACE) regimen has also been developed for use in
refractory patients who are candidates for HDT (Lee et al. 2003).
In addition, the integration of thalidomide into combination
chemotherapy regimens for the treatment of previously untreated
multiple myeloma is currently under investigation. 
Radiation therapy
Hemibody radiation therapy for multiple myeloma has been used
as a consolidation following induction combination chemotherapy
or as salvage therapy for chemotherapy-resistant myeloma
(Thomas et al. 1984; Mackenzie et al. 1992). Total body irradiation
can also be used as a component of ablative therapy before SCT.
Unmet needs in the treatment of multiple myeloma
Ultimately, there is a need to be able to characterize multiple
myeloma as a treatable condition in the future rather than as an
incurable condition, through improvements in OS, delaying disease
progression, and improving CR rates. In view of this, the
development of treatments with mechanisms of action distinct from
cytotoxic chemotherapy would be advantageous and improvements
in the efficacy of first-line treatments are highly desirable. There is
also a paucity of data on the economic burden imposed by multiple
myeloma and on the cost effectiveness and cost utility of treatments. 
Clinical evidence for the role of bortezomib in
the treatment of multiple myeloma
The 20S proteasome plays a crucial role in the maintenance of
intracellular homeostasis in eukaryotic cells (Adams 2004).
Bortezomib (LDP-341, MG-341, MLN-341, PS-341, Velcade) is a
dipeptide boronic acid that reversibly inhibits the 
chymotrypsin-like proteolytic activity site of the 20S proteasome
(Adams 2002), which induces apoptosis, reverses drug resistance
in multiple myeloma cells, and which influences their
microenvironment by blocking cytokine circuits, cell adhesion, and
angiogenesis in vivo (Hideshima et al. 2001; LeBlanc et al. 2002;
Hideshima et al. 2003). 
Bortezomib received full approval in 2005 from the US Food and
Drug Administration (FDA) for the treatment of multiple myeloma
patients who have received at least one prior therapy 
(Kane et al. 2006) on the basis of the results of safety and efficacy
data from the Assessment of Proteasome inhibition for EXtending
remissions (APEX) trial. This large international trial included 
669 patients with relapsed multiple myeloma who received either
intravenous bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of
cycles one through eight (21-day cycles) and on days 1, 8, 15,
and 22 of cycles nine to eleven (35-day cycles), for a maximum
treatment period of 273 days; or oral high-dose dexamethasone
(40 mg) on days 1 to 4, 9 to 12, and 17 to 20 of cycles one through
four (35-day cycles) and on days 1 to 4 of cycles five through nine
(28-day cycles), for a maximum treatment period of 280 days
(Richardson et al. 2005a). 
The first approval of bortezomib in patients with relapsed or
refractory multiple myeloma was secured in 2003 on the basis 
of two generally well-conducted phase II clinical trials. 
A small-scale, open-label, randomized Clinical Response and
Efficacy Study of bortezomib in the Treatment of refractory
myeloma (CREST) was performed in 54 patients who received
intravenous bortezomib 1.0 or 1.3 mg/m2 on days 1, 4, 8, and 11
in a 21-day cycle for up to eight cycles with response rates of 30
and 38%, respectively, to bortezomib alone (Jagannath et al.
2004). In addition, a multicenter, nonrandomized, open-label,
phase II Study of Uncontrolled Myeloma Managed with
proteasome Inhibition Therapy (SUMMIT) was conducted in
which 27% of 202 heavily pretreated patients who received
intravenous bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 in a
21-day cycle for up to eight cycles had CR or PR to bortezomib
alone (Richardson et al. 2003).
Extensions and subanalyses of APEX, CREST, and SUMMIT have
been reported (Berenson et al. 2005; Lonial et al. 2005;
Richardson et al. 2005a; Dubois et al. 2006; Richardson et al.
2006). In addition, there are numerous reports of the use of
bortezomib in previously untreated patients and in combination
regimens. Since these are in abstract form, they are referenced
but full appraisal is not possible.
Patient-oriented evidence
There is good evidence of significant efficacy for bortezomib in
the prolongation of OS, improvements in 1-year survival rate, and
prolongation of time to progression (TTP) (Table 3) in patients with
relapsed or refractory multiple myeloma. 
Overall survival 
In the APEX trial, OS was significantly longer among patients who
received bortezomib, both for those who had received one previous
treatment (hazard ratio 0.42; P=0.01) and for those who had
received more than one previous treatment (hazard ratio 0.63;
P=0.02) (Richardson et al. 2005a). The survival advantage for
patients receiving treatment with bortezomib was retained even
though 147 patients (44%) in the dexamethasone group, who had
disease progression, were crossed over to receive bortezomib in a
companion study. As a result of early closure of the dexamethasone
group, the median follow-up of surviving patients in both groups
was limited to 8.3 months and the median survival time could not
be calculated (Richardson et al. 2005a) (Table 3). A subsequent
report updated the survival analysis based on median follow-up 
of 22 months (Richardson et al. 2005c). Median OS was 
29.8 months in the bortezomib group compared with 23.7 months
Bortezomib | clinical impact review
Core Evidence 2006;1(4)with dexamethasone (P=0.02), despite more than 62% of
dexamethasone patients crossing over to bortezomib. Median
survival appeared to be longer for patients receiving bortezomib
earlier rather than later.
The two open-label, phase II clinical trials [Richardson et al. 2003
(SUMMIT); Jagannath et al. 2004 (CREST)], and an observational
analysis of compassionate use of bortezomib (Wu et al. 2005),
have also provided some evidence on OS in patients with
relapsed or refractory multiple myeloma although OS was 
not a primary study endpoint and/or follow-up was of 
insufficient duration. In the CREST trial, median survival was not
reached for all patients randomized to both bortezomib dose
groups (1.3 mg/m2 vs 1.0 mg/m2), during a median duration of
follow-up of 26 months. However, the study was only powered 
to assess the response rate to bortezomib and thus the 
patient population (n=54) was too small to allow an adequate
assessment of survival (Jagannath et al. 2004). In contrast, in the
nonrandomized SUMMIT trial, updated median survival among 
all 202 patients with relapsed or refractory multiple myeloma 
was 17.2 months (Richardson et al. 2004), and 17 months in 
193 evaluable patients after extended follow-up (Richardson et al.
2006a). A subanalysis of the SUMMIT trial found that lower 
OS was associated with factors indicative of greater tumor
burden (e.g. bone marrow plasma cell infiltration >50%,
hypoalbuminemia, thrombocytopenia) (Richardson et al. 2005b).
1-year survival rate
The APEX trial also provides good supporting evidence that
bortezomib produces a superior level of survival after 1 year than
conventional therapy (oral high-dose dexamethasone) in patients
with relapsed multiple myeloma. The between-treatment difference
was highly statistically significant (Table 3) and reflected a 
41% reduction in the risk of death in the bortezomib group during
the first year after enrollment (Richardson et al. 2005a). The updated
follow-up to APEX showed 1-year survival rates were of 80 and
67%, respectively (P=0.0002), for bortezomib and dexamethasone
(Richardson et al. 2005c). A systematic review (in abstract form)
reported 1-year survival rates of 81% for bortezomib compared with
67% for thalidomide (P<0.001; n=6 studies) (Prince et al. 2005).
A small-scale, open-label, nonrandomized study of bortezomib alone or
in combination with dexamethasone in patients with previously
untreated multiple myeloma has also estimated that the 1-year survival
rate would have been 87% of patients. However, the calculation was
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Level of 
evidence
Design Treatment and dose Outcomes Reference
OS 1-year survival rate TTP/PFS
2 Open, RCT, n=669 pts
with relapsed multiple
myeloma
BOR 1.3 mg/m2 (i.v.) 
High-dose DEX 40 mg
(oral)
OS was significantly
longer with BOR than
DEX, in pts with one
or >1 previous
treatment (HR 0.42
and 0.63, respectively)
BOR 80% (P=0.003)
DEX 66%
Median TTP 
6.22 months (189 d)
(P<0.0001) 
Median TTP 
3.49 months (106 d)
Richardson et al.
2005a (APEX)
2 Open, RCT, n=669 pts
with relapsed multiple
myeloma 
BOR 1.3 mg/m2 (i.v.) 
High-dose DEX 40 mg
(oral)
Median OS
29.8 months
Median OS
23.7 months
BOR 80% (P=0.0002) 
DEX 67%
Median TTP 
6.2 months
Median TTP 
3.5 months
Richardson et al.
2005c (APEX update)
2 Open, RCT, n=54 pts
with relapsed
refractory multiple
myeloma
BOR 1.3 mg/m2 (i.v.)
BOR 1.0 mg/m2 (i.v.)
(alone or in combination
with oral DEX 20 mg)
Median OS not
reached 
Median OS
26.7 months
(813 d)
– Median TTP 
11.0 months (333 d)
Median TTP 
7.0 months (212 d)
Jagannath et al. 
2004 (CREST)
3 Open, n=202 pts with
relapsed refractory
multiple myeloma
BOR 1.3 mg/m2 (i.v.)
(alone or in combination
with oral DEX 20 mg)
Median OS
17.2 months 
– Median TTP 
7 months with BOR 
1.3 mg/m2 vs 3 months
during the last
treatment prior to
enrollment (P=0.01)
Richardson et al.
2003, 2004, 2006
(SUMMIT)
BOR, bortezomib; d, day; DEX, dexamethasone; HR, hazard ratio; i.v., intravenous; M, melphalan; OS, overall survival; PFS, progression-free survival; pts, patients; RCT, randomized controlled
trial; TTP, time to progression.
Table 3 | Summary of outcome evidence for bortezomib in APEX, CREST, and SUMMIT: overall survival, 1-year survival rate, and
median time to progression/progression-free survival in patients with multiple myeloma271
based on a relatively short duration of follow-up (median 5.5 months) in
a small number of patients (n=32) (Jagannath et al. 2005a). 
Prolongation of TTP
There is evidence that bortezomib produces a highly statistically
significant prolongation of TTP (median 6.22 months) compared
to conventional therapy (median 3.49 months) in patients with
relapsed multiple myeloma in the APEX trial (Richardson et al.
2005a) (Table 3). These results are consistent with those of the
previous SUMMIT trial, which indicated that bortezomib alone or
in combination with dexamethasone produced a significantly
longer median TTP than the patients’ last treatment prior to
enrollment (Table 3) (Richardson et al. 2003). Of particular note in
the APEX trial was the observation that median TTP was even
longer (7.0 months) in bortezomib-treated patients who had
received only one previous treatment (Richardson et al. 2005a). In
the APEX trial, disease progression led to early discontinuation in
98 patients who received bortezomib (29%) and in 174 (52%) who
received dexamethasone (P<0.001) (Richardson et al. 2005a).
Adverse events
The APEX trial provides supporting evidence for the tolerability
profile of bortezomib in patients with relapsed multiple myeloma
(Table 4) (Richardson et al. 2005a) which is consistent with the
results of the CREST and SUMMIT trials (Richardson et al. 2003;
Jagannath et al. 2004).
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Level of
evidence
AE incidence Comparators Study population Reference
2 Grade 3 AEs (61%) (P<0.01 vs DEX)
Grade 4 AEs (14%)
Serious AEs (44%)
Grade 3/4 thrombocytopenia (30%)
All (including grade 3) peripheral neuropathy (36%)
Grade 3 AEs (44%)
Grade 4 AEs (16%)
Serious AEs (43%)
Grade 3/4 thrombocytopenia (6%)
All and grade 3 peripheral neuropathy (9%)
BOR 1.3 mg/m2 (i.v.) 
High-dose DEX 40 mg (oral)
n=669 pts with relapsed multiple
myeloma
Richardson et al.
2005a (APEX)
2 Combined grade 4 AEs (9%)
Grade 3/4 thrombocytopenia (26%). 
All peripheral neuropathy (41%)
Grade 3 peripheral neuropathy (9%)
BOR 1.3 mg/m2 (i.v.) vs BOR 1.0 mg/m2
(i.v.) (alone or in combination with oral
DEX 20 mg)
n=54 pts with relapsed refractory
multiple myeloma
Jagannath et al.
2004 (CREST)
3 Grade 4 AEs (14%)
Grade 3/4 thrombocytopenia (31%)
All peripheral neuropathy (34%)
Grade 3 peripheral neuropathy (12%) 
BOR 1.3 mg/m2 (i.v.) (alone or in
combination with oral DEX 20 mg)
n=202 pts with relapsed refractory
multiple myeloma
Richardson et al.
2003 (SUMMIT)
3 Grade 3/4 thrombocytopenia (29%)
Grade 3/4 diarrhea (11%)
Grade 3/4 anemia (11%)
Grade 3/4 neutropenia (10%)
BOR 1 or 1.3 mg/m2 (i.v.) (alone or in
combination with oral DEX 20 mg)
n=63 pts with relapsed refractory
multiple myeloma
Berenson et al.
2005a
3 Grade 3/4 neutropenia (40%)
Grade 3/4 thrombocytopenia (40%)
Grade 3/4 anemia (28%)
BOR 0.7–1 mg/m2 (in combination with
M 0.025–0.25 mg/kg)
n=35 pts with relapsed refractory
multiple myeloma
Berenson et al.
2006
3 Grade 3 thrombocytopenia (50% of cycles)
Peripheral neuropathy (10% of cycles)
BOR 1.3 mg/m2 (i.v.) (alone or in
combination with oral or i.v. DEX 20 mg)
n=7 pts with relapsed refractory
multiple myeloma
Lee et al. 2005a 
3 Grade 3/4 thrombocytopenia (19%)
Grade 3 leucopenia (5%)
Grade 3 peripheral neuropathy (5%)
Grade 3 vasculitis (5%)
BOR 1.3 mg/m2 (i.v.)  n=21 pts with relapsed refractory
multiple myeloma
Musto et al. 2006
4 All peripheral neuropathy (47%)
Grade 3 peripheral neuropathy (20%)
All thrombocytopenia (25%)
Grade 3 thrombocytopenia (17%)
BOR 1.3 mg/m2 (i.v.) [plus high-dose M
and autologous stem cell support
(n=29) or allogeneic SCT (n=8)]
n=50 pts with relapsed or refractory
multiple myeloma
Wu et al. 2005
aExtension of CREST and SUMMIT.
AE, adverse event; BOR, bortezomib; DEX, dexamethasone; i.v., intravenous; M, melphalan; pts, patients; SCT, stem cell transplant.
Table 4 | Summary of outcome evidence for bortezomib: adverse events in patients with multiple myelomaGastrointestinal events, thrombocytopenia, and peripheral
neuropathy occurred more frequently in the bortezomib group
than in the dexamethasone group and grade 3 adverse events
were significantly more frequent in the bortezomib group than in
the dexamethasone group (P<0.01). Improvement or resolution of
grade 2 or higher peripheral neuropathy was noted in 44 of
87 patients (51%) in whom it developed during bortezomib
treatment (median time to resolution 107 days). In an updated
analysis of APEX, 120 of 331 patients developed peripheral
neuropathy, including 91 with grade ≥2 (San Miguel et al. 2005).
Of these,  30 had grade ≥3, and 68 required dose modification
including 31 who discontinued treatment. However, neuropathy
improved in 26 of 37 patients requiring dose modification (all with
complete resolution of symptoms in a median of 78 days), in 19
of the 31 patients discontinuing bortezomib (resolution in 17)
within 121 days, and in 12 of 23 within a median of 106 days
without dose modification. Similarly, Richardson et al. (2006b)
reported improvement or resolution of symptoms in 25 of the 35
patients with grade ≥3 neuropathy or who discontinued
bortezomib treatment in the SUMMIT and CREST trials.
Thrombocytopenia was essentially transient and reversible in
nature. The most common grade 3/4 adverse events (reported in
>10% of patients in either group) were thrombocytopenia,
anemia, and neutropenia in the bortezomib group in contrast with
anemia in the dexamethasone group. However, the bortezomib
group and the dexamethasone group had similar rates of grade
4 and serious adverse events. A total of 121 of 333 patients in the
bortezomib group (37%) and 96 of 336 in the dexamethasone
group (29%) had adverse events necessitating early
discontinuation of treatment. A dose-escalation study reported a
maximum tolerated dose of bortezomib 1 mg/m2 (in combination
with melphalan 0.1 mg/kg), with grade 4 neutropenia as the
dose-limiting toxicity in two of six in the high-dose cohort
(Berenson et al. 2006). An extension to the CREST and SUMMIT
trials found that continued treatment with bortezomib for a
median of 45 weeks did not result in cumulative toxicity
(Richardson et al. 2005b).
The thrombocytopenia seen with bortezomib appears to be
reversible, with platelet counts recovering between treatment
cycles and the pretreatment count increasing during subsequent
cycles (Lonial et al. 2005). It appears to be the result of a
reversible effect on megakaryocytic function rather than direct
cytotoxicity.
Skeletal events
Osteolytic lesions weaken the bones of patients with multiple
myeloma, causing pain and increasing the risk of fractures 
(MMRF 2005a). The median time to a first skeletal event in
patients with relapsed multiple myeloma treated with either
bortezomib or dexamethasone could not be calculated in the
APEX trial in which all patients also received treatment with
bisphosphonates for bone disease (Richardson et al. 2005a). Data
on skeletal events have not been reported in other published
bortezomib studies in patients with multiple myeloma. Thus, it is
currently not possible to evaluate whether bortezomib has any
effect on the incidence of fractures in patients with multiple
myeloma. However, a retrospective analysis of SUMMIT and
APEX trial data has indicated that bortezomib treatment produced
rapid elevation of alkaline phosphatase in responding patients
(CR+PR) in the absence of other liver function abnormalities,
which suggested that it may promote osteoblastic activity
(Zangari et al. 2005). 
Infections
The overall rate of grade ≥3 infections was not significantly
different between the bortezomib and dexamethasone arms of
the APEX trial (13 and 16%, respectively). However, the incidence
of herpes zoster infection was significantly more frequent during
treatment with bortezomib (13%) than with dexamethasone  (5%;
P<0.001). These infections were manageable with appropriate
antiviral therapy (Richardson et al. 2005a) and in the SUMMIT
study, grade 4 neutropenia, related febrile neutropenia, and
sepsis were rare (Richardson et al. 2003). 
Quality of life
APEX provides some evidence that bortezomib is associated with
better health-related quality of life (HRQOL) than high-dose
dexamethasone in the treatment of patients with relapsed
multiple myeloma (Lee et al. 2005b). Two HRQOL instruments
were used in APEX [European Organisation for Research and
Treatment of Cancer (EORTC) Quality of Life Questionnaire
(QLQ)-C30 and Functional Assessment of Cancer Therapy
Gynecologic Oncology Group—Neurotoxicity (FACT/GOG-NTX)].
Over 42 weeks a significant difference in favor of bortezomib was
found for the primary endpoint of Global Health, as well as the
secondary endpoints of Physical, Role, Cognitive, and Emotional
Functioning, and the symptom scales of Nausea, Dyspnea, Sleep,
Diarrhea, and Financial Impact. There were no HRQOL domains in
which high-dose dexamethasone was shown to be superior 
(Lee et al. 2005b).
Further supporting evidence has also come from an analysis of
quality of life among 143 patients in the SUMMIT trial, in which
improvements in the mean global quality of life score and
disease symptoms, including pain and fatigue, suggested that
bortezomib improved patients’ wellbeing. Patients with a CR or
PR also had a general improvement in global and physical
domain scores on the QLQ-C30, as well as a decrease in the
severity of symptoms of disease, pain, and fatigue (Richardson
et al. 2003). This has been further corroborated in another
subanalysis of the SUMMIT trial (Dubois et al. 2006). Patient-
reported outcomes (PROs), as assessed by the QLQ-C30, the
myeloma-specific QLQ-MY24, the Functional Assessment of
Chronic Illness Therapy (FACIT) Fatigue scale, and the
FACT/GOG-NTX scale, showed an improvement between best
endpoint and baseline. PRO scores correlated with response,
with significant differences between the improvements seen in
responding patients compared with deteriorations in PRO
scores in nonresponders. Fatigue significantly improved with
bortezomib, whereas neuropathy scores were largely
unchanged. Improvements in role, social, and future perspective
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using different definitions of improvement (>5, >3 points, effect
size >0.2, effect size >0.5, >10% change from baseline). Global
quality of life improved in more than 35% of patients for all
improvement definitions apart from effect size >0.5.
Disease-oriented evidence 
Response rates and duration of response
Complete responses are rare in patients with relapsed/refractory
multiple myeloma. There is good evidence supporting the
efficacy for bortezomib in terms of response rates (CR+PR)
(Table 5) and also for duration of response (Table 5), as defined
by stringent EBMT criteria, in patients with relapsed or refractory
multiple myeloma. In particular, CR+PR rates of up to 50% with
single-agent bortezomib are noteworthy in this population.
Recently, a response rate of 61% (14 of 23 patients) has been
reported for bortezomib, but patient numbers are small (Bruno et
al. 2006). The median duration of response to bortezomib in
extended follow-up in the SUMMIT trial was 12.7 months
(Richardson et al. 2006a). A systematic review (in abstract form)
reported overall response rate, using EBMT criteria, of 36% for
bortezomib compared with 22% for thalidomide (P<0.001; n=4
studies) (Prince et al. 2005).
More complete suppression of M protein levels may be correlated
with more complete reduction of the myeloma cell mass and with
longer survival (Bross et al. 2004). In the APEX extended follow-
up, patients with greater M protein reduction tended to have
longer duration of response (Richardson et al. 2005c). In the
SUMMIT trial, it was found that achievement of CR or PR to
bortezomib alone was associated with significantly longer survival
than that in all other patients (P=0.007) (Richardson et al. 2003),
and with longer median TTP (13.9 vs 7 months in overall patient
population) (Richardson et al. 2006a).
Interestingly, first response to bortezomib was seen in 54% of
patients after cycle 2, including 29% on or after cycle 4 and 
7% on or after cycle 6; approximately 20% of patients responding
to bortezomib achieved maximal M protein suppression on or
after cycle 8 (Richardson et al. 2005c). 
A subanalysis of the SUMMIT trial revealed that better response to
bortezomib was associated with younger age (response rate 32% in
patients aged <65 years vs 19% in those over 65; P<0.05), and with
plasma cell infiltration in bone marrow of ≤50% (35% response rate
vs 20% with >50% infiltration; P<0.05) (Richardson et al. 2005b).
Evidence is emerging for the use of bortezomib in patients with
relapsed or refractory myeloma in combination with melphalan
Level of
evidence
Design Treatment and dose Outcomes Reference
Response rate Response duration
2 Open, RCT, n=669
pts with relapsed
multiple myeloma
BOR 1.3 mg/m2 (i.v.) 
High-dose DEX 40 mg (oral)
CR+PR rate 38% (P<0.001) 
CR rate 6% (P<0.001)
nCR rate 7% (P<0.001)
CR+PR rate 18%
CR rate <1%
nCR rate 1%
Median duration of response 
8 months 
Median duration of response 
5.6 months
Richardson et al. 2005a
(APEX)
2 Open, RCT, n=669
pts with relapsed
multiple myeloma
BOR 1.3 mg/m2 (i.v.) 
High-dose DEX 40 mg (oral)
CR+PR rate 43% 
CR rate 9% 
nCR rate 7%
CR+PR rate 18%
CR rate <1%
nCR rate 1%
Median duration of response 
7.8 months 
Median duration of response 
5.6 months
Richardson et al. 2005c
(APEX update)
2 Open, RCT, n=54
pts with relapsed
refractory multiple
myeloma
BOR 1.3 mg/m2 (i.v.)
BOR 1.0 mg/m2 (i.v.) 
(alone or in combination 
with oral DEX 20 mg)
CR+PR rate 50% 
CR rate 4% 
CR+PR rate 37%
CR+nCR rate 19%
Median duration of response 
13.7 months 
Median duration of response 
9.5 months 
Jagannath et al. 2004
(CREST)
3 Open, n=202 pts
with relapsed
refractory multiple
myeloma
BOR 1.3 mg/m2 (i.v.) 
(alone or in combination 
with oral DEX 20 mg)
CR+PR rate 27% 
CR+nCR rate 10%
Median duration of response
12–12.7 months 
Richardson et al. 2003,
2006 (SUMMIT)
BOR, bortezomib; CR, complete response; DEX, dexamethasone; i.v., intravenous; MR, minimal response; nCR, near-complete response; PR, partial response; pts, patients;
RCT, randomized controlled trial.
Table 5 | Summary of outcome evidence for bortezomib in APEX, CREST, and SUMMIT: CR and PR rate, and duration of response
(CR+PR+MR) in patients with multiple myeloma
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(V-MPT) (Palumbo et al. 2005); melphalan, dexamethasone, 
and thalidomide (VMDT) (Terpos et al. 2005); dexamethasone,
thalidomide, and zoledronic acid (VTD-Z) (Teoh et al. 2005);
pegylated liposomal doxobubicin and dexamethasone (VDD)
(Jakubowiak et al. 2005); pegylated liposomal doxobubicin 
and melphalan (Chari et al. 2005); dexamethasone and
cyclophosphamide (Kropff et al. 2005); or prednisone and
cyclophosphamide (Reece et al. 2005). These ongoing studies,
most of which are still recruiting and have small numbers of
patients, report promising results with response rates of over 50%.
Economic evidence
It is likely that, during the treatment of multiple myeloma, every
patient will receive all the available treatments and therefore the
cost of each treatment will have to be met. Thus a key question
for hematologists is what combination should they receive the
treatments in and in what sequence to give the patient the best
chance of survival. Some limited information on the cost
effectiveness of bortezomib in patients with relapsed refractory
multiple myeloma has been derived from the results of the 
single-arm, phase II SUMMIT study (Richardson et al. 2003). 
The objective of this retrospective analysis, which was
conducted from the viewpoint of third party (e.g. health plan) or
government healthcare payers in the USA, was to assess the
cost effectiveness of bortezomib relative to current therapeutic
options [thalidomide and best standard care (BSC) and
thalidomide] (Mehta et al. 2004). The results of the analysis
suggest that the clinical benefits of bortezomib, in terms of
response, delay in disease progression, and improved OS, could
be derived at a reasonable cost [incremental cost-effectiveness
ratio (ICER) $US45 356 per life-year gained], relative to
thalidomide and BSC, in patients with relapsed refractory
multiple myeloma. In addition, sensitivity analyses, which varied
the prices  of bortezomib and thalidomide, the proportion of
patients sing bisphosphonates, frequencies of chronic events,
frequency of skeletal events, and median survival by ±25%,
indicated that these results were robust and reproducible
(Mehta et al. 2004).
The demographic, clinical, and limited medical resource-
utilization data for the bortezomib group were derived from the
results of the SUMMIT study, but were derived from expert
opinion and published sources for the comparator thalidomide
plus BSC group. The ideal data source would have been a
sufficiently powered, head-to-head, randomized controlled
trial. This expert panel approach has been used in health
services research but it has been criticized for comparing data
from different sources and on the basis of potential loss of
objectivity, although it may have added an element of external
validity to the clinical trial data in the cost-effectiveness
analysis. The decision analysis model used in this study did not
attempt to incorporate the indirect costs of multiple myeloma
treatment, which have not been well quantified. However, it did
include the relevant direct costs associated with treatment of
multiple myeloma, which was a valid approach to economic
analysis from a payer’s viewpoint.
In addition, an assessment of the cost effectiveness of bortezomib
from a UK NHS perspective, which also utilized medical 
resource-utilization data from SUMMIT, has been published,
although only in abstract form. This analysis reported that the cost
effectiveness of bortezomib (ICER £17 161–33 539 per life-year
gained), based on a mean additional survival benefit of 8–12 months,
with good quality of life, compared favorably to other currently used
salvage therapies (Bagust et al. 2004). A further analysis from a UK
perspective estimated a cost per patient of £16 772, and cost per
100 000 population of £33 545, based on APEX trial data, UK prices,
and UK incidence rates (Anon. 2006). The authors also estimate a
cost per life-year gained of £117 404 with bortezomib. 
However, additional economic studies of bortezomib compared
to thalidomide and BSC that include quality of life measures are
required, and data on the cost utility of the treatment of multiple
myeloma with bortezomib are not yet available. 
Resource utilization
Medical resource utilization in the treatment of multiple myeloma
falls into three broad components: pharmacotherapy used to delay
disease progression; disease management (i.e. concomitant
medications, consultations, and diagnostic tests); and management
and avoidance of adverse events (Mehta et al. 2004). In the
American cost-effectiveness analysis of bortezomib based on the
SUMMIT study, published sources of cost data were used to
retrospectively assign unit costs to medical resource utilization
components (Mehta et al. 2004). The costs of concomitant
treatment with bisphosphonates and analgesics were included in
the model, along with blood testing, bone marrow biopsy, and
skeletal surveys. In addition, the management of both chronic
adverse events (anemia requiring red blood cell transfusion or
erythropoietin or thrombocytopenia that required platelet
transfusions) was included along with acute adverse events 
(grade 3/4 infections, skeletal complications, hypercalcemia, central
nervous system disturbances, fatigue, peripheral neuropathy, deep
vein thrombosis, and gastrointestinal disorders). However, it was
unclear if it included the costs of antiviral therapy for management
of shingles. Patients treated with bortezomib were assumed to have
received between three and eight cycles of therapy while those in
the comparator group were assumed to have received thalidomide
for as long as they continued to respond (mean duration 6 months
for responders and 2 months for nonresponders). In this model, from
the viewpoint of US healthcare payers, the total medical resource
utilization costs (including therapy, disease management, and
adverse events) for a bortezomib-treated patient with relapsed
refractory multiple myeloma were $US65 222, compared with
$US14 423 for a patient receiving BSC, based on median OS of 16
and 2.5 months, respectively (Mehta et al. 2004). However, since
17% of the patients in the study had not had thalidomide, a stratified
model was developed to analyze the potential benefit of thalidomide
in these patients. In the stratified model, the total medical resource
utilization costs for patients with prior thalidomide use were
$US69 200 and $US14 423 based on median OS of 15.7 and
2.5 months for bortezomib and BSC, respectively. On the other
hand, the costs for patients without prior thalidomide use were
$US68 816 and $US 37 265 based on median OS of 26 and
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8.6 months for bortezomib and thalidomide, respectively. Thus, the
use of thalidomide or BSC was less expensive overall than bortezomib
but this may, at least in part, be due to the shorter duration of patients’
survival compared to bortezomib. However, healthcare payers that
provide coverage for patients with multiple myeloma will have to reach
their own decisions regarding balancing the resource impact versus
the clinical outcomes achieved with bortezomib. 
Patient group/population
The evidence to support the use of bortezomib in its licensed
indication as a single agent for the treatment of progressive multiple
myeloma patients who have had at least one prior therapy, and who
have already undergone or are unsuitable for bone marrow
transplantation, was provided primarily by the international,
randomized, phase III APEX trial that compared bortezomib
favorably with oral high-dose dexamethasone (Richardson et al.
2005a). The patient populations included in these studies had
measurable PD after one-to-three previous treatments, Karnofsky
performance status scores ≥60, platelet count ≥50 000/mm3, and an
absolute neutrophil count ≥750/mm3 (Richardson et al. 2005a). The
response to bortezomib was not influenced by standard prognostic
factors in patients with relapsed refractory multiple myeloma
(Richardson et al. 2005b). These included gender, type of myeloma,
serum level of beta 2-M, type, and number of previous therapies.
Age ≥65 years was however loosely associated with lower response
in SUMMIT (Richardson et al. 2003; Richardson et al. 2005a).
Furthermore, there is good evidence, from both the SUMMIT and
APEX trials, that responses to bortezomib were unaffected by
chromosome 13 deletion, which predicts a poor outcome with
conventional therapy (Richardson et al. 2003; Jagannath et al.
2005b). This observation has been corroborated elsewhere (Drach et
al. 2005). Additionally, there is good evidence from a limited number
of patients in the SUMMIT study that bortezomib is feasible in
patients with impaired renal function (Jagannath et al. 2005c), and
may be given to patients with renal failure receiving hemodialysis
(Chanan-Khan et al. 2005).
There is a growing body of evidence on the use of bortezomib in
combination regimens, giving promising results in patients with
relapsed or refractory myeloma.
Dosage, administration, and formulations
Bortezomib (LDP-341, MG-341, MLN-341, PS-341, Velcade) is a
modified dipeptide boronic acid. It is available for intravenous
injection as a sterile lyophilized powder in single-dose vials
containing 3.5 mg bortezomib and 35 mg mannitol, USP. The
lyophilized powder drug product is reconstituted with 0.9% NaCl
to a final concentration of 1 mg/mL before injection. 
Bortezomib is indicated for the treatment of multiple myeloma
patients who have received at least one prior therapy. The
recommended dose of bortezomib is 1.3 mg/m2 per dose
administered as a 3–5 second bolus intravenous injection twice
weekly for 2 weeks (days 1, 4, 8, and 11) followed by a 10-day rest
period (days 12–21) for a maximum recommended number of eight
cycles. At least 72 hours should elapse between consecutive doses
of bortezomib (Anon. 2005). Bortezomib therapy should be withheld
at the onset of any grade 3 nonhematologic or grade 4 hematologic
toxicities, excluding neuropathy. Once the symptoms of the toxicity
have resolved, bortezomib therapy may be reinitiated at a 25%
reduced dose (i.e. 1.3 mg/m2 per dose reduced to 1.0 mg/m2 per
dose; or 1.0 mg/m2 per dose reduced to 0.7 mg/m2 per dose) (Anon.
2005). No dose modification is required if grade 1 peripheral sensory
neuropathy (paresthesias and/or loss of reflexes) occurs but, if it
occurs with pain or at the grade 2 (interfering with function but not
activities of daily living), the dose of bortezomib should be reduced
to 1.0 mg/m2. If grade 2 neuropathy occurs with pain, or at the grade
3 (interfering with activities of daily living), bortezomib should be
discontinued until the toxicity is resolved and then reinitiated at 0.7
mg/m2 once weekly. Bortezomib therapy should be discontinued in
patients with grade 4 (disabling) neuropathic pain/peripheral sensory
neuropathy, and patients with preexisting severe neuropathy should
be treated with bortezomib only after careful risk–benefit
assessment (Anon. 2005).
Clinical value
Bortezomib produces significant prolongation of OS and TTP
compared with standard oral high-dose dexamethasone treatment
in patients with relapsed multiple myeloma following 1–3 prior
therapies, albeit with an increased incidence of grade 3 adverse
events and herpes zoster infections. There is some evidence 
that improved clinical outcomes with bortezomib compared to 
high-dose dexamethasone are also accompanied by significantly
improved HRQOL. 
The APEX trial provides good level 2 evidence, but the fact that it was
stopped early as a result of significantly improved survival and TTP in
the bortezomib patients initially limited the availability of longer-term
survival benefit. However, an extended follow-up to APEX confirms
that the survival benefit is maintained, despite over 62% of the
patients from the high-dose dexamethasone arm crossing over to
bortezomib (Richardson et al. 2005c). After a median follow-up of 
22 months, median OS was 29.8 months in the bortezomib group
compared with 23.7 months for dexamethasone. Despite these
encouraging results, the trial has been criticized in the UK where the
relevance of dexamethasone as a comparator may not mirror clinical
practice, unlike the rest of Europe and North America (Anon. 2006).
Clearly, the higher acquisition cost of bortezomib compared with
thalidomide and BSC is an issue but there is some evidence that
the clinical benefits of bortezomib, in terms of response, delay in
disease progression, and improved OS, can be derived at a
reasonable cost in patients with relapsed refractory multiple
myeloma. While there may be higher unit cost, the length of therapy
also needs to be considered; bortezomib was given for a median of
six cycles in APEX, while the thalidomide or dexamethasone
regimen was typically administered until progression, thus incurring
the cost over a longer period (up to 1 year).
Bortezomib is the first and only single agent that has
demonstrated a survival advantage for patients with relapsed or
refractory multiple myeloma, and the current evidence supports
its use as a valuable treatment option for this patient population. 
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